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Hospital, Eindhoven, The Netherlands and 3The Northern Hospital, Sheffield, UKA recent article by Mike Wyatt, published in the
European Journal of Vascular and Endovascular
Surgery,1 has high-lighted the important contributions
made by EUROSTAR and the UK RETA registries to
our understanding of the pitfalls as well as the
potential clinical benefits of endovascular aneurysm
repair (EVAR) during its early developmental phases.
In the decade, since these registries started recruiting
patients they have recorded a rapid uptake of the
procedure in Europe, despite the absence of definitive
evidence of superior efficacy in comparison to the
established methods for treating aortic aneurysms.
But, this year we have seen further highly notable
European contributions to knowledge in this area with
publication of the UK EVAR and Dutch DREAM Trial
results2,3 and we do now have level 1 evidence in
support of EVAR for relatively fit patients. Somewhat
counter intuitively, the UK EVAR 2 trial showed no
benefit for EVAR over non-interventional conservative
management in patients deemed unfit for convention-
al open repair4 and it would seem that strenuous
measures to address their co-morbidities, as effectively
as possible, is to be preferred to early EVAR for these
individuals.
Given the present state-of-play it is timely to
consider the future of the EVAR Registries. Some
may question whether they have any useful role at all
following publication of the randomised trial results.
On the contrary, it is our case that not only do the
EVAR registries have a future but that, far from being
diminished, their value to the vascular community
may be enhanced considerably in the post-randomised
trial era. There are three reasons for this. First, there isng author. P. Harris, MD, FRCS, Regional Vascular
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evaluation of endograft technologies, which may well
evolve at an even faster rate given scientific proof of
efficacy, which is likely to boost the confidence of
industrial companies and encourage increased invest-
ment in research and development. Secondly, there are
applications of EVAR technology that have not been
subjected to the test of randomised trials, for example
endovascular repair of thoracic aneurysms and the
application of fenestrated and branched endografts for
treatment of complex juxtarenal and thoraco-abdomi-
nal aneurysms. Endovascular repair of thoracic
aneurysms is already well-established treatment,
which, by common consent, should probably not be
subjected to a randomised controlled trial (RCT)
because the perceived benefits over open repair in
terms lower operative mortality and morbidity are
such that few, if any clinicians are left in any doubt
about its advantages, i.e. equipoise does not apply.
However, especially in the absence of data from any
RCT, careful monitoring of the outcomes of treatment
is essential and should probably be a mandatory
regulatory requirement. Both EUROSTAR and RETA
have ongoing thoracic registries, which must be
continued. Thirdly, the dissemination of EVAR as
mainstream treatment in most vascular units through-
out Europe raises serious issues about quality control.
Issues that the registries could, and in our view
should, be adapted to address.
Although, the randomised trials have shown
statistically significant benefit for EVAR when
compared to open repair it is important to appreciate
that the margin of benefit was relatively small and
attributable, entirely, to a difference in operative
mortality rates. There was a survival advantage for
EVAR over conventional open repair (OR) of just three
percent at 30 days (EVAR 1; 1.7 versus 4.7%). And thisEur J Vasc Endovasc Surg 30, 343–345 (2005)
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ished after 4 years of follow up. Such a small margin is
at risk from being cancelled out by any relaxation of
clinical standards, specifically relating to patient
selection and technical performance of the procedure
itself. Therefore, there are requirements for bench-
marking and comparative audit as tools for quality
control that are both essential and urgent. The
EUROSTAR and RETA registries have always served
to provide these to their contributors, but as a
secondary rather than a primary function and on a
voluntary rather than a mandatory basis.5,6
In the USA, the value of registries for quality control
has been recognised and is being acted upon. Both the
lifeline EVAR registry and the recently initiated ASVS
registry on carotid artery stenting and endarterectomy
are being adapted for this function. We propose that
EUROSTAR and other European national EVAR
registries, such as RETA should be similarly utilised.
To render EUROSTAR ‘fit for purpose’ in this context,
the following three essential prerequisites will need to
be satisfied.An Authoritative and Stable Administrative
Structure
To date EUROSTAR has depended entirely upon the
efforts and goodwill of a small number of committed
individuals, but this arrangement cannot be
sustained indefinitely and is, therefore, inherently
unstable. Just as the ‘Lifeline’ registry is maintained
under the auspices of the American Society for
Vascular Surgery, we propose that the EUROSTAR
registry should be placed under the governance of the
European Society for Vascular Surgery. In our view it
would be an asset to The Society by enabling it to offer
additional important services to its members, and to
the European vascular community at large. RETA,
which was established originally under the joint
auspices of the British Society for Interventional
Radiology (BSIR) and the Vascular Society of Great
Britain and Ireland (VSGBI) has always benefited from
some financial and administrative support provided
by these national representative organisations.Secure Funding
EUROSTAR currently has two sources of funding; (i)
income from contracts agreed with commercial
companies in return for the provision of confidential
‘device-specific’ analyses, and (ii) a fee paid by the
Belgian RIZIV (Rijksinstituut voor ziekte- enEur J Vasc Endovasc Surg Vol 30, October 2005invaliditeitsverzekering) in connection with a contract
to maintain the Belgian national EVAR registry. As far
as the commercial companies are concerned, it has
been possible to agree short-term contracts only and
continued income from this source cannot be guaran-
teed. Also a reduction in the number of companies
with commercially successful EVAR products has had
negative impact upon the finances of EUROSTAR. The
Belgian RIZIV contract terminates early in 2006 and,
with it, all income from this source. There is a strong
case to be made for continued funding by commercial
companies. But, without compulsion, this alone is
unlikely to secure the financial stability required. In
the USA there are moves, by the Food and Drugs
Administration (FDA) to make the commercial
companies directly responsible for the funding of
statutory data collection. Perhaps similar demands
could be made by the regulatory authorities in Europe.
The ESVS could give security to EUROSTAR by
underwriting financially the registry programme,
without necessarily providing direct funding under
normal circumstances. Additionally, given its position
as a bone fide international EUROPEAN organisation
with a large membership representing all EU states,
the ESVS could add considerable weight to appli-
cations for EEC funding in support of the EUROSTAR
programme, which is, after all, a valuable source of
specific health care information for European
populations.Comprehensive and Complete Data Collection
Because participation in the EUROSTAR project is
entirely voluntary, data collection is neither compre-
hensive nor complete. The best we can hope for is that
the data submitted are reasonably representative of
practice in European Hospitals as a whole. For
effective benchmarking this is not good enough. Data
collection needs to be both comprehensive and
complete, i.e. all centres undertaking EVAR should
be required to submit all relevant data on all eligible
patients. Electronic data transmission facilitates this
process considerably and EUROSTAR provides this to
its contributors. Compulsory data submission is not a
universally popular concept and is difficult to enforce.
However, it is in the interests of national healthcare
systems to ensure that all EVAR data are collected and
analysed and perhaps other countries could follow the
Belgian example by making verifiable data submission
a prerequisite for reimbursement of the procedure.
Whether or not compulsion is considered practical
universally, the ESVS could do a great deal to influence
its members to comply with basic requirements for
Editorial 345quality assurance through comparative audit by
setting and monitoring standards, utilising the facili-
ties of EUROSTAR.
The point about individual countries needing to
collect and analyse nationally derived data is an
important one. EUROSTAR even under the auspices
of the ESVS would have difficulty in servicing this
need. In the post-randomised trials era surely those
countries that have not done so already will wish to
establish a national EVAR registry. National auth-
orities are in the best position to ensure that data
collection is as comprehensive as possible, which is an
important advantage associated with this approach.
One option for meeting everyone’s needs might be for
European national registries, like RETA, to be linked
through EUROSTAR under the auspices of the ESVS.
By this means vascular centres could submit just one
set of data that would serve several purposes. Issues of
confidentiality and governance, especially in respect
of under-performing centres, arise and will need to be
dealt with effectively and with appropriate sensitivity.
But, these should not be accepted as obstacles to
sensible progress.
A recent survey of all EUROSTAR participants
revealed that 87% of respondents supported
continuance of the programme in the post-randomised
trial era. There are many other individuals and
organisations around the world, without direct
involvement in the programme, who have benefited
from it and who also wish to see it continue. Certainly,
a change of emphasis is necessary if it is to respond
adequately to the challenges of benchmarking andcomparative audit that apply today. And, most
importantly, it must ‘move on’ in respect of its
infrastructure if it is to endure. Early incorporation
into the ESVS is possibly the only realistic option for
securing a viable future for the EUROSTAR
programme.References
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